Bibliografia
Dettmar PW, Hampson FC, Jain A, Choubey S, Little SL, Baxter T.
Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole. Indian J Med Res. 2006 Apr;123(4):517-24.
Dettmar PW, Little SL, Baxter T.
The effect of omeprazole pre-treatment on rafts formed by reflux suppressant tablets containing alginate. J Int Med Res. 2005 May-Jun;33(3):301-8.
De Bellis I et al.
Il reflusso gastro-esofageo in gravidanza. Giorn It Ost Gin; 21(1): 17-19, 1999.
Eriksen CA et al. Combined cimetidine-alginate
antacid therapy versus single agent treatment for reflux esophagitis. Results
of prospective double-blind randomised clinical trial. Ann Chir et Gynaecol;
77: 133-137, 1998.
Poynard T et al. Randomized, multicentre
comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated
gstro-oesophageal reflux. Aliment Pharmacol Ther; 12: 159-165, 1998.
Taminiau JAJM. Gastro-oesophageal reflux in children. Scand
J Gastroenterol 32 Suppl 223: 18-20, 1997.
Klotz F et al. A double blind trial
of alginate sodium versus ranitidine in the treatment of patients with erosive
oesophagitis grade I. Poster Presentation, II United European Gastro-enterology
Week, Barcelona, July 19-24, 1993.
Poynard T et al. Relapse rate of
patients after healing of oesophagitis - a prospective study of alginate as a
self-care treatment for six months. Aliment Pharmacol Ther; 7: 385-392, 1993.
Poynard T et al. Relapse rate of
patients after healing of oesophagitis - a prospective study of alginate as a
self-care treatment for six months. Aliment Pharmacol Ther; 7: 385-392, 1993.
Vandenplas Y et al. A proposition
fo the diagnosis and treatment of gastro-oesophageal reflux disease in children:
a report from a working group on gastro-oesophageal reflux disease. Eur J Pediatr 152: 704-711, 1993.
Le Luyer B et al. Etude clinique
multicentrique de l'alginate de sodium dans le traitement des régurgitations
du nourrisson; Ann Pediatr 39: 635-640, 1992.
Washington N. In: Antiacids and anti-reflux
agents. CRC Press, 209-211, 1991.
Le Luyer B et al. Efficacité pharmacologique
de l'alginate de sodium suspension sur le reflux gastro-oesophagien du nourrisson
et de l'enfant. Arch Fr Pediatr; 47: 65-68, 1990.
Washington N et al. Effect of time
of dosing relative to a meal on the raft formation of an anti-reflux agent. J
Pharm Pharmacol; 42(1): 50-53, 1990.
Washington N. Investigation into the barrier
action of an alginate gastric reflux suppressant, Liquid Gaviscon. Drug Invest;
2(1): 23-30, 1990.
Uzan M et al. Pyrosis et régurgitations au
cours de la grossesse. Efficacité et innocuité d'un traitment par
Gaviscon suspension. Rev fr Gynécol Obstét;83(7-9): 569-572, 1988.
Washington N et al.
Gastric distribution and residence time of two anti-reflux formulations. Jnt
Pharm; 39: 163-171, 1987
Washington N et al.
What is "Liquid Gaviscon"? A comparison of four international formulations.
Int J Pharm; 34: 105-109, 1986
Washington N et al. Evaluation
of "raft forming" antiacid neutralizing capacity: in vitro and in vivo
correlations. I J Pharm; 27: 279-286, 1985.
May HA et al. Monitoring radiolabelled
antiacid preparations in the stomach. Int J Pharm; 19: 169-176, 1984.
Chevrel B. A comparative crossover study on the treatment
of heartburn and epigastric pain: Liquid Gaviscon and a magnesium aliminium antacid
gel J Int Med Res; 8(4): 300-302, 1980.
Malmud LS et al. The mode of action
of alginic acid compound in the reduction of gastroesophageal reflux. J Nucl
Med, 20: 1023-1028, 1979.
Williams DL et al. The symptomatic
treatment of heartburn and dyspepsia with Liquid Gaviscon: a multicentre general
practitioner study. J Int Med Res; 7: 551-555, 1979.
Barnardo DE et al. A double-blind controlled trial
of Gaviscon in patients with symptomatic gastro-oesophageal reflux. Curr Med
Res Opin, 3: 388-391, 1975.
|
